RxDoctor Payments Data

Victor Evans

Child & Adolescent Psychiatry · Lexington, SCNPI 1386703700

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $18,076 of the $25,858 with a category attached, or 69.9%. 16 manufacturers reported payments, led by Takeda Pharmaceuticals U.S.A., Inc. at 58.2% of the total. Reporting peaked in 2019 at $11,740 and has fallen 95.1% since, to $579 in 2025. Among child & adolescent psychiatry clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$25,858in general payments, 2019–2025

Across 271 payments — averaging $95.42 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$15K
  • Tris Pharma Inc$6K
  • Corium, LLC$3K
  • Supernus Pharmaceuticals, Inc.$645
  • Johnson & Johnson$361
  • Ironshore Pharmaceuticals Inc.$176
  • plus $637 from 10 others

What the payments were for

  • Consulting fees$3601%
  • Speaking & faculty fees$18,07670%
  • Travel & lodging$2,62110%
  • Food & beverage$4,78118%
  • Education$00%
  • Gifts$200%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$25,858 in reported general payments places this provider in the 95th percentile of 71 child & adolescent psychiatry providers in South Carolina.

See all child & adolescent psychiatry providers in South Carolina

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide33$18,586
Lisdexamfetamine Dimesylate11$2,986
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine30$747
Bupropion XlBupropion Hcl20$512
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine21$333
Alprazolam17$99
Clonazepam11$53

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix$15,060$18,58633 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 71 child & adolescent psychiatry providers in South Carolina.

Other child & adolescent psychiatry in Lexington

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →